When it comes to identifying cancer, there's no such thing as too early. Later this year, we expect to launch the GlycoKnow™ Colon test, which is being developed as a laboratory-developed risk assessment test that uses glycopeptide and peptide biomarkers to assess the presence of adenomas with high-grade dysplasia or colorectal cancer. When developed, a single blood draw should be able to put patients with an increased risk of colon cancer on the path to receiving care before a tumor has developed.
GlycoKnow Colon is intended to be complementary to—and not a replacement for—current recommended colorectal cancer testing methods.
InterVenn’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). Our tests are developed, and the performance characteristics are determined by InterVenn. Our tests have not been cleared or approved by the U.S. Food and Drug Administration. InterVenn’s clinical laboratory is regulated under CLIA to perform high-complexity testing. Our tests are not intended for clinical purposes.
|Proof of Concept||Classifier Validation||LDT Validation||Commercially Available|
|GLORI™||Pelvic Mass Triaging|
|DAWN™ IO Melanoma||Immuno-Therapy Response Prediction|
|Non-Small Cell Lung Carcinoma (NSCLC)||Immuno-Therapy Response Prediction|
|GlycoKnow™ Colon||Pre-Malignant Detection, Cancer Prevention|
Expected Launch in 2023
|Multiple Cancer Early Detection: Breast, Colon, Lung, Pancreas, Prostate||Early Detection|
|Treatment Monitoring Panel: Autoimmune||Disease Monitoring|
|Treatment Monitoring Panel: Inflammation||Disease Monitoring|
|Treatment Monitoring Panel: Infectious Disease||Disease Monitoring|